Mumbai: Pharmaceutical firm Aurobindo Pharma Ltd said on 12 May it has received approval from the Medicines Control Council (MCC) to manufacture and market nine products in South Africa.
These products are said to have a generic market size of 165 million South African rands in the local market, the company informed the Bombay Stock Exchange.
Aurobindo now has 31 marketing authorizations approved by the MCC, the company added.
Out of the nine products — Zinoxime and Yomax — are anti-infective while Auro-Lisinopril Co, Auro-Amlodipine and Lisinozide are cardio-vascular drugs.
The other products that received the approval include — Auro-Finasteride, Zolid, Lazivir and Profina.
The firm’s shares were trading at Rs330, down 2.21% on the BSE in afternoon trade.